IRNA agents targeting VEGF
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsAntonin Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil Rajeev, Philipp Hadwiger
Life of this patent
Estimating the term…
Abstract
The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
Claims20
An isolated iRNA agent, comprising a sense sequence and an antisense sequence, wherein the sense and the antisense sequences form an RNA duplex, and wherein the antisense sequence comprises a nucleotide sequence sufficiently complementary to a target sequence of about 19 to 23 nucleotides of a VEGF nucleotide sequence and wherein said target sequence differs by no more than 1, 2, or 3 nucleotides from a sequence selected from the group consisting of SEQ ID NOs:1-401.
Dependencies are inferred from the claim text.